“We’re delighted to work with Emma and look forward to combining her extensive knowledge of K2P channel biology with Metrion’s ion channel discovery knowledge”, commented Dr Eddy Stevens, CSO at Metrion.

How advancements in ion channel drug discovery are developing research in the field of pain management

We are proud to be included in the Business Weekly Killer50 Life Sciences Ones2Watch for 2025

One of the critical contributors to the development of epilepsy is ion channel dysfunction. We focus on a selection of ion channels that can be involved.

Metrion shortlisted as 'Employer of the Year'

Lysosomal ion channels: TRPML1, TRPML2, TRPML3, TMEM175, and TPC2.

Whether you're a small biotech managing tight budgets or a large pharma striving for efficiency, Metrion is here to help you do more with less.

We mark Rare Disease Day by highlighting a selection of the most detrimental ion channel mutations which can result in a plethora of rare diseases, often involving complex neurological, cardiac, and muscular manifestations.

"The data is always correct and is in a format that imports directly into our systems, making it so quick and easy for our team to review the data across individual projects."

Insight into the history of how automated patch clamp has contributed to enhancing decision making, minimising risk and lowering R&D costs